BCP
AMRX icon

BlackBarn Capital Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

BlackBarn Capital Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.5M Buy
1,650,000
+80,000
+5% +$1.07M 1.65% 14
2025
Q4 		$19.8M Sell
1,570,000
-619,452
-28% -$7.09M 1.3% 11
2025
Q3 		$21.9M Sell
2,189,452
-1,257,118
-36% -$11.3M 1.57% 9
2025
Q2 		$27.9M Buy
3,446,570
+564,916
+20% +$4.26M 1.6% 5
2025
Q1 		$24.1M Buy
2,881,654
+31,654
+1% +$264K 1.54% 7
2024
Q4 		$22.6M Buy
2,850,000
+438,388
+18% +$3.68M 1.24% 7
2024
Q3 		$20.1M Buy
2,411,612
+411,612
+21% +$3.22M 2.64% 5
2024
Q2 		$12.7M Buy
2,000,000
+586,703
+42% +$3.72M 1.13% 7
2024
Q1 		$8.56M Buy
+1,413,297
New +$7.97M 4.84% 10

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return